

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT3127244

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
JANSSEN-CILAG	05/30/2012
RECEIVING PARTY DATA	
Name:	JANSSEN PHARMACEUTICA NV
Street Address:	TURNHOUTSEWEG 30
City:	BEERSE
State/Country:	BELGIUM
Postal Code:	B-2340
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	14404188
CORRESPONDENCE DATA	
Fax Number:	(518)452-5579
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	(518)452-5600
Email:	jdp@hrfmlaw.com
Correspondent Name:	ERICA M. HINES
Address Line 1:	5 COLUMBIA CIRCLE
Address Line 2:	HESLIN ROTHENBERG FARLEY & MESITI P.C.
Address Line 4:	ALBANY, NEW YORK 12203
ATTORNEY DOCKET NUMBER:	3084.156A
NAME OF SUBMITTER:	ERICA M. HINES
SIGNATURE:	/Erica M. Hines/
DATE SIGNED:	12/01/2014
Total Attachments: 1	
source=3084156A_JanssenCilagJanssenPharma (H0042503xD16FB)#page1.tif	

General Assignment

WHEREAS, Janssen-Cilag, having its place of business at 1 rue Camille Desmoulins, TSA 91003, 92787 Issy-les Moulineaux Cedex 9, France (hereinafter referred to as "Assignor"), is the owner of certain new and useful inventions relating to

"NEW COMPOUNDS"

for which on the 30th day of May 2012, United Kingdom Patent Application no. 1209609.5 was filed at UK Intellectual Property Office;

on the 30th day of May 2012, USA Patent Application no. 61/653140 was filed at USPTO; and

on the 14th day of March 2013, USA Patent Application no. 61/782210 was filed at USPTO.

WHEREAS, Janssen Pharmaceutica NV, having its place of business at Turnhoutseweg 30, B-2340 Beerse, Belgium (hereinafter referred to as "Assignee") is desirous of acquiring Assignors' entire right, title and interest therein, including the right to claim priority thereof,

NOW, THEREFORE, BE IT KNOWN, that in view of good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Assignor hereby assigns and transfers, for all countries in the world, to said Assignee its entire right, title and interest, including the right to claim priority, in and to all said inventions disclosed in said applications and in and to said applications, and all foreign equivalents thereof, including all substitutions, divisions, and continuations thereof, and in and to all Letters Patent, that may be granted for said inventions, and in and to all extensions, renewals, and reissues thereof, the same to be held and enjoyed by said Assignee, its successors and assigns, as fully and entirely as the same would have been held and enjoyed by Assignor if this Assignment had not been made.

And for purpose of obtaining patent protection in any foreign country, the Assignor hereby agrees that, any right, title and interest, in and to all said inventions disclosed in said applications and in and to said applications, and all foreign equivalents thereof can be directly assigned by the inventors to the Assignee without explicit confirmation of the Assignor.

The Assignor agrees that this general assignment is effective from the 30th day of May 2012.


IN TESTIMONY WHEREOF, the Assignor and Assignee set hereunto their hand and seal this date.

For Janssen-Cilag



.....
Frank Daelemans, Proxy Holder
Janssen-Cilag

For Janssen Pharmaceutica NV



.....
Luc Quaghebeur, Proxy Holder
Janssen Pharmaceutica NV